医学
生长激素缺乏
PEG比率
不利影响
聚乙二醇
内科学
加药
内分泌学
激素
生长激素
生物化学
化学
财务
经济
作者
Zhouhong Jiang,Xuefeng Chen,Guanping Dong,Yin Lou,Jianping Zhang,Xinran Cheng,Jiayan Pan,Wei Liao,Jinzhun Wu,Xiaodong Huang,Xianjiang Jin,Deyun Liu,Ting Zeng,Shunye Zhu,Qin Dong,Xiaoming Luo,Dan Lan,Lizhi Cao,Xingxing Zhang,Jing Liu
标识
DOI:10.3389/fphar.2022.955809
摘要
Objective: Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong®) is the first long-acting rhGH preparation that is approved to treat children with growth hormone deficiency (GHD) in China. Clinical experience with dose selections of PEG-rhGH is scarce. The present study compared the efficacy and safety of a lower dose to increase dosing regimens of PEG-rhGH treatment. Methods: A multicenter, randomized, open-label, dose-comparison clinical study was conducted to compare the improvements in the height standard deviation score (Ht SDS), height velocity (HV), insulin-like growth factor-1 (IGF-1) SDS, and safety profiles of children with GHD who are treated with 0.2 mg/kg/week of PEG-rhGH dose or 0.14 mg/kg/week for 26 weeks. Results: Ht SDS, HV, and IGF-1 SDS increased significantly after PEG-rhGH treatment in the two dose groups (p < 0.05). The improvements of Ht SDS, HV, and IGF-1 SDS were more significant in the high-dose group than in the low-dose group (p < 0.05). Ht SDS improvement in low-dose group was not non-inferiority to that in the high-dose group (p = 0.2987). The incidences of adverse events were comparable between the two groups. Conclusion: The improvements of Ht SDS, HV, and IGF-1 SDS were more significant in the high-dose group than in the low-dose group (p < 0.05). PEG-rhGH at the dose of 0.14 mg/kg/week was effective and safe for children with GHD. Clinical Trial Registration: clinicaltrials.gov , identifier NCT02908958.
科研通智能强力驱动
Strongly Powered by AbleSci AI